



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :

G01N 33/68, C07K 1/04

A1

(11) International Publication Number:

WO 95/16918

(43) International Publication Date:

22 June 1995 (22.06.95)

(21) International Application Number: PCT/US94/08542

(22) International Filing Date: 26 July 1994 (26.07.94)

(30) Priority Data:

08/168,966

15 December 1993 (15.12.93)

US

(71) Applicant: COMBICHEM, INC. [US/US]; Suite 230, 10975 Torreyana Road, San Diego, CA 92121 (US).

(72) Inventor: BRENNER, Sydney; 17B St. Edwards Passage, Cambridge CB2 3PJ (GB).

(74) Agents: WEISS, Steven, M. et al.; Lyon &amp; Lyon, 34th floor, 611 West Sixth Street, Los Angeles, CA 90017 (US).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(54) Title: COMBINATORIAL LIBRARIES AND METHODS FOR THEIR USE

## (57) Abstract

Kit, and method for its use and construction, which includes a first plurality of vessels containing different polysubunits, each constructed from a known number of subunits. Each subunit is joined by one or more bonds and each subunit and bond can be the same or different. Each of the different polysubunits has a different sequence of subunits but has the same known subunit at one terminus. Each vessel contains polysubunits which have a different known subunit at one terminus. The kit further includes a second plurality of vessels which includes different polysubunits, each constructed from the known number minus one subunit, as described above.



Each pool contains 16 molecules. There are a total of 64 unique molecules.

Scheme 1. A depiction of the split pool synthesis of a combinatorial library with an alphabet of 4 and a degree of 3. After each step of the synthesis, a portion of each sublibrary is saved and catalogued before the randomization step.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTION

## COMBINATORIAL LIBRARIES AND METHODS FOR THEIR USE

This application is a continuation-in-part of U.S. application Serial No. 08/168,966, filed December 15, 1993, which is a continuation of U.S. application Serial No. 07/978,646, filed November 19, 1992.

5

Background of the Invention

This invention relates to synthetic combinatorial libraries useful for drug discovery, and methods for their use in such drug discovery.

Houghten et al., 354 Nature 84, 1991 and  
10 WO 92/09300 (PCT/US91/08694), describe the generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. These libraries are composed of mixtures of free peptides which form a heterogenous library. Systematic identification of optimal peptide  
15 ligands is achieved by screening a library followed by iterative selection and synthesis processes. For example, one library consisted of a series of six residue peptides having the first two positions specifically defined, and the last four positions consisting of a random mixture of  
20 18 L-amino acids. This library was screened to determine which pair of defined peptides had optimum activity in an assay. A second library was then synthesized in which the optimal pair of peptides were included, the third position of each peptide individually synthesized, and the last  
25 three peptides consisted of a random mixture of 18 L-amino acids. This library was screened as before and the process repeated until the optimum six residue peptide was identified. Houghten et al. state:

"A number of other libraries, such as one  
30 composed entirely of D-amino acids, have been prepared which in total permit the systematic screening of hundreds of millions of peptides.

A fundamental feature of SPCLs [synthetic peptide combinatorial libraries] is that free peptides can be generated and used in solution in virtually all existing assay systems at a concentration of each peptide most applicable to the assay. This approach has also been successfully used in radio-receptor assays (opioid peptides) and plaque inhibition assays (human immunodeficiency virus (HIV-1) and Herpes Simplex Virus (HSV)). SPCLs, as described, greatly aid all areas of drug discovery and research involving peptides."

Lam et al., 354 *Nature* 82, 1991, and WO 92/00091 (PCT/US91/04666) and Houghten et al., 354 *Nature* 84, 1991 and WO 92/09300 (PCT/US91/08694), describe systematic synthesis and screening of peptide and other libraries of defined structure. The method used by Lam et al. is based on a one bead one peptide approach in which a large peptide library consisting of millions of beads are screened. Each bead contains a single peptide. The authors state:

"It is clearly not enough to use a random mixture of activated amino acids in a peptide synthesis protocol, because the widely different coupling rates of different amino acids will lead to unequal representation and because each bead will contain a mixture of different peptides. Our solution was to use a 'split synthesis' approach. The first cycle consisted of distributing a pool of resin beads into separate reaction vessels each with a single amino acid, allowing the coupling reactions to go to completion, and then repooling the beads. The cycle was repeated several times to extend the peptide chain. In this fashion, each bead should contain only a single peptide species."

The library of beads was screened by a staining procedure and stained beads visualized using a microscope, and removed. The structure of the peptide is obtained by a chemical analysis of the material on the single bead.

5 Lam et al. indicate:

"Additionally, our approach has far greater potential for applying the richness of well-established peptide chemistry to synthesize libraries incorporated D-amino acids or  
10 unnatural amino acids as well as specific secondary structures including cyclic peptides. All of this can be accomplished without need to keep records of the synthetic products as our interest is focused just on those peptides which  
15 provide a strong interaction signal with the acceptor."

#### Summary of the Invention

The present invention features an efficient method for the construction and decomposition of  
20 combinatorial libraries to allow identification of useful polysubunit compounds (made up from two or more subunits which may be the same or different, referred to sometimes as polymers). The method is not limited to identification of polypeptides; it can be applied to any combination of  
25 compounds made up of differing subunits (referred to sometimes as monomeric compounds) within one polysubunit compound. Synthesis of such polysubunits can be carried out chemically or with the use of catalysts, including enzymes. Thus, for example, the subunits may be selected  
30 from natural or unnatural moieties, including amino acids, nucleotides, sugars, lipids, and carbohydrates. In addition, the bond used to attach each subunit to the prior subunit can make any desired type of bond, and may include covalent, ionic or coordination bonds. The bonds  
35 may be selectively cleavable by enzymes or chemical treatments, as desired. Examples of such bonds include: peptide [ $R^1\text{CONHR}^2$ ], ester [ $R^1\text{COOR}^2$ ], sulfonamide [ $R^1\text{SO}_2\text{NR}^2$ ],

thioester  $[R^1\text{COSR}^2]$ , phosphodiester  $[R^1\text{OPOR}^2]$ , ether  $[R^1\text{COCR}^2]$ , thioether  $[R^1\text{CSCR}^2]$ , phosphamide  $[R^1\text{PONH-}]$ , amine  $[-\text{CH}_2\text{NHC-}]$ , and azo  $[-\text{CNNC-}]$  (where each  $R^1$  and  $R^2$  may be the same or different and may be cyclic or acyclic). In the method, a free or solid-phase-bound polysubunit can be used to allow ready screening of the synthesized polysubunits in any desired test or assay system. A significant advantage of this invention is that it provides a series of libraries or collections of polysubunits which can be reused for screening for any number of desired properties in any chosen assays.

The present method does not employ a mixed synthesis in which several different subunits are chemically incorporated within one vessel, but rather a synthesis in which a single subunit is incorporated at each step. See Figure 1.

Thus, in one example, the method involves a first step of attaching ten different subunits A, B, C . . . J, to a solid support in ten separate vessels or columns. In the second step, a portion or aliquot of the material synthesized at the first step is retained as separate columns, while the remainder (which is still attached to individual solid supports) is mixed or pooled, divided into ten new different columns, and ten further parallel syntheses carried out to provide the dimer  $\text{XA}^1$ ,  $\text{XB}^1$ ,  $\text{XC}^1$  . . .  $\text{XJ}^1$ , where X is any one of the original A-J, and  $\text{A}^1$ ,  $\text{B}^1$ ,  $\text{C}^1$  . . .  $\text{J}^1$  are ten different subunits which may be the same or different from A-J. Of course, fewer or more than ten syntheses can be used in this second step. In the third step, a portion of the newly synthesized material of step two is again retained in separate columns, and the remainder mixed and divided into ten further columns so that the synthetic procedure can be repeated until the whole length of the desired polysubunit is synthesized. In this way a series of vessels is formed at each step, differing from those in prior steps by the presence of an extra subunit.

The final ten columns in the above example (each having a variety of different polysubunits with a known subunit at their terminus) can be assayed using any standard assay format. That is, each of the ten mixtures is assayed to determine which mixture contains one or more active compounds. The column which is found to contain an active compound identifies the subunit required at the polysubunit terminus to be active in the assay. For example, the column containing polysubunits of sequence XXXXJ<sup>1</sup> may be active in the assay. This indicates that J<sup>1</sup> is required at the terminus of a polysubunit in this assay. This subunit is now bonded to each of the columns retained in the previous synthetic step (in the example, the columns XXXA, XXXB, . . . XXXJ). These ten newly synthesized series of compounds can then be assayed and the process repeated until the final polysubunit sequence is known. See Figures 2 and 3.

Thus, the method of the present invention features a set or kit of partial combinatorial libraries with each library containing one subunit more than the prior library. The final library is decomposed stepwise starting with the last subunit. This form of retroanalysis or antithesis allows definition of the synthesis of the desired product, which is accomplished in the final analytic step. Once constructed, the entire set of libraries can be used for many different projects.

Thus, in a first aspect, the invention features a kit which includes a first plurality of vessels containing different polysubunits, each constructed from a known number of subunits. Each subunit is joined by one or more bonds, and each subunit and bond can be the same or different. Each of the different polysubunits has a different sequence of subunits, but has the same known subunit at one terminus. Each vessel contains polysubunits which have a different known subunit at their terminus. The kit further includes a second plurality of vessels which includes different polysubunits, each

constructed from the known number minus one subunit, as described above.

This kit forms a combinatorial library which can be screened and decomposed as discussed above. The number  
5 of first and second pluralities of vessels can be the same or different, and generally the terminus of the polysubunits to which subunits are added is the same in each set of vessels.

In preferred embodiments, the kit may include  
10 further pluralities of vessels in which the number of subunits present in the polysubunit is the known number minus two, or three, or more. Thus, each plurality of vessels differs from other pluralities of vessels in the number of subunits present in the polysubunits. Most  
15 preferably, the number of subunits in each plurality of vessels differs by one and ranges from one to the known number. As discussed above, such a kit is useful for systematic identification of the sequence of a desired polysubunit, using the method of retroanalysis.

20 As noted above, the polysubunits may be formed from any series of subunits desired, and the number of vessels containing these polysubunits at each step can be different for each subunit added. Thus, as described above, ten amino acids may be incorporated in one step,  
25 two or three carbohydrates may be incorporated in another step, and twenty amino acids in the following step. There is no limit to the steps of addition of subunits, nor to the choice of subunits which can be added at each step. All that is necessary for the kit to be useful is that the  
30 kit include a series of vessels which contain polysubunits differing sequentially in the number of subunits present in those polysubunits. The final plurality of vessels in the kit will contain only the first subunit free in solution, or bound to a solid support.

35 In a related aspect the invention features, a method for construction of a kit, following the steps



described above, and a method for screening such kits as described above.

Specifically, the invention features a method for construction of a kit useful for identification of a  
5 desired compound, by the steps of: (a) providing a first plurality of vessels containing different polysubunits each constructed from a known number of subunits joined together by one or more bonds. Each subunit and bond can be the same or different, and each different polysubunit  
10 has a different sequence of subunits but the same known subunit at one terminus of the polysubunit. Each vessel includes polysubunits having a different known subunit at their terminus; (b) combining aliquots of the different polysubunits from each vessel to form a mixture; wherein  
15 the aliquots are less than all of the contents of each vessel; (c) dividing the mixture into a second plurality of vessels; and (d) bonding a further subunit to each polysubunit in the second plurality of vessels; wherein the subunit is different for each second plurality of  
20 vessels.

In preferred embodiments, the method further includes repeating steps (a) through (d) for the second plurality of vessels; or repeating steps (a) through (d) a plurality of times.

25 In a related aspect, the invention features a method for identification of a desired compound, including the steps of: (a) providing a kit as described above, and screening the first plurality of vessels to identify a vessel having a desired activity in an assay, and thereby  
30 identifying a first known subunit; and (b) coupling the first known subunit to a terminus of an aliquot of the contents of each of the different polysubunits in the second plurality of vessels.

In preferred embodiments, the method further  
35 involves screening the different polysubunits having the first known subunit for the desired activity in the assay,

and thereby identifying a second known subunit; or repeating steps (a) and (b) a plurality of times.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

#### Description of the Preferred Embodiments

The drawings will first briefly be described.

##### Drawings:

Figure 1 illustrates split pool synthesis of a combinatorial library.

Figure 2 illustrates utilization of the deconvolution pathway to determine the sequence of a member of a combinatorial library.

Figure 3 illustrates the deconvolution of a pentapeptide library.

Figure 4 illustrates the corrected absorbances of pools of library products reacted with  $\beta$ -endorphin antibody to determine the sequence of the pentapeptide which bound best to the  $\beta$ -endorphin antibody.

Applicant has determined that a useful series, or kit, of libraries can be constructed by stepwise synthesis of a polysubunit from different subunits. While these libraries and methods for their synthesis and use will commonly be applied for use with peptides formed from standard L- or D-amino acids, those of ordinary skill in the art will recognize that other subunits and bonds other than covalent, ionic or coordination bonds can be used to form the final polysubunit, which can then be screened in any standard assay. These synthetic protocols and assays are well known to those of ordinary skill in the art and need not be repeated here. See, Lam et al., *supra*, and Houghten et al., *supra*, the whole of all of which are hereby incorporated by reference herein. As an illustrative example of a method and kit of this invention, the following is provided. This example is not limiting in the invention and those of ordinary skill will

realize (as noted above) that other equivalent methods, syntheses, and analyses can be readily used.

Example

The method proposed here is based on a true  
5 combinatorial synthesis and makes efficient use of all of  
the materials. The first step is to attach ten subunits,  
A to J, to a solid support in ten columns. One-sixth of  
this material is retained in this form, giving A, B, . .  
. J; the remainder, still attached to the solid support,  
10 is pooled, divided into ten columns, and ten parallel  
syntheses are carried out, to provide XA, XB, . . . XJ.  
One-fifth of this material is retained in this form, and  
the combinatorial synthesis is repeated to give ten  
polysubunits, XXA, XXB, . . . XXJ. One-fourth is kept and  
15 the fourth residue is added to the remainder by  
combinatorial synthesis to give the polysubunits XXXA,  
XXXB, . . . XXXJ. After retaining one-third of these  
polysubunits the final combinatorial step of synthesis is  
completed, and the materials are removed from the column  
20 to provide ten solutions containing XXXXA, XXXXB, XXXXJ.  
These are now assayed.

If a positive assay result is obtained with one  
vessel containing polysubunits of the structure XXXXC  
(i.e., C is the critical subunit at the fifth position in  
25 the pentasubunit), the experimenter returns to the columns  
retained at the previous step, and to an aliquot of each  
adds C, to provide ten solutions, XXXAC, XXXBC . . .  
XXXJC. Again, these are tested. If a positive assay  
result is obtained with XXXEC (i.e., E is the critical  
30 subunit at position four in the pentasubunit), the  
experimenter returns to the previous partial library and  
completes it by adding E + C to all ten to give XXAEC,  
XXBEC . . . XXJEC. These steps are repeated until all of  
the positions are specified.

35 Thus, in essence a set of partial combinatorial  
libraries is made, each one residue longer than the last.  
The final library is decomposed stepwise, starting with

the last residue. This form of retro-analysis allows definition of the synthesis of the desired product, which is indeed accomplished in the very last step. Once constructed, the entire set of libraries can be used again  
5 for different projects.

It is notable that the final synthetic step also provides a method for synthesis of the desired product.

#### Materials and Methods

**Solvents.** DMF (HPLC grade) was purchased from  
10 Baxter and was used without further purification.  $\text{CH}_2\text{Cl}_2$  was purchased from Fisher Scientific and was distilled over  $\text{CaH}_2$  before use.

**Instrumentation.** UV absorbances were measured on a Hewlett-Packard 8452A diode array spectrophotometer.  
15 All centrifugations were carried out on an Eppendorf 5415 C centrifuge for one minute at 10,000 rpm.

**Formation of the Pentapeptide Library.** The peptide libraries were synthesized manually by a solid phase method. Tentagel (TG) resin was the solid support  
20 for all synthesis and was 90  $\mu\text{m}$  in diameter. The amino acids used for the formation of the libraries were Gly-FMOC, Leu-FMOC, Phe-FMOC and Tyr(tBu)-FMOC. All amino acids were coupled with the aid of HBTU and DIPEA. The Tentagel, HBTU, DIPEA and amino acids used were purchased  
25 from NovaBiochem. Tentagel was added to 4 glass fritted filter vials, shaken with DMF and filtered. To each vial was added one of the FMOC protected amino acid components of the library, HBTU, DMF and 20  $\mu\text{l}$  DIPEA. All four vials were shaken for one hour, filtered and washed with DMF.  
30 A 5% solution (v/v) of acetic anhydride in DMF was added to each vial and shaken for 20 minutes to cap any uncoupled free amino acid groups. The beads were then filtered, washed with DMF (2x) and  $\text{CH}_2\text{Cl}_2$  (2x) and dried for two hours in a vacuum oven (55°C at 20 mm Hg).  
35 Approximately, a 75 mg portion of the amino acid coupled Tentagel bead was taken from each vial and labeled in a manner describing the length of the peptide and the

- identity of the last amino acid coupled. Also, an approximately 5 mg portion of the resin was taken to do an FMOC deprotection test in order to quantitate the completeness of the previous amino acid coupling step.
- 5 The remaining resin was combined and shaken in 3:1 (v/v) DMF/CH<sub>2</sub>Cl<sub>2</sub> for 30 minutes to randomize the beads. The beads were quartered into equivalent weight (and therefore equivalent moles) and set into 4 glass fritted filter vials and subjected twice to 10 minute shakings with 20%
- 10 Piperidine in DMF (v/v) in order to cleave the N-terminal FMOC protecting group. The beads were filtered, washed with DMF (3x) and coupled with one of the 4 amino acid components of the library to give the 4 dipeptide pools, TG-Xaa-Gly-FMOC, TG-Xaa-Leu-FMOC, TG-Xaa-Phe-FMOC, and TG-
- 15 Xaa-Tyr(tBu)-FMOC. The steps of 1) capping the peptide with acetic anhydride, 2) saving and labeling a 75 mg portion of the resin, 3) combining, randomizing and evenly dividing the beads and 4) coupling each division with an FMOC protected amino acid was repeated until the 5th
- 20 coupling. At this point there are 4 pentapeptide libraries. These pentapeptide libraries were cleaved of the t-butyl protecting group on the tyrosines by mixing the resin with TFA (Pierce) for 2 hours. The beads were filtered and washed with ethanol (2x) and DMF (2x). The
- 25 beads were then shaken with 20% Piperidine in DMF (v/v) twice for 10 minutes to cleave the N-terminal FMOC group. The deprotected beads were then washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub> (2x) and set in a vacuum oven overnight (55°C at 20 mm Hg) to evaporate any residual solvent.
- 30 **ELISA Procedure.** The library containing Tentagel resin (~3 mg) was added to a polypropylene tube. The tube was coated with a 1:1 (v/v) blocking solution of 3% BSA in PBS (w/v) and .05% Tween-20 (Sigma) in PBS (v/v). The tube was incubated with 500 µl of a 1:1:1
- 35 (v/v/v) solution consisting of 1 µg/ml mouse anti-β-endorphin monoclonal antibody (Boehringer Mannheim) in PBS, 3% BSA in PBS and .05% Tween-20 in PBS at 37°C for

one hour. The tube was centrifuged and the supernatant was decanted. The tube was washed 3 times by repetitively adding 0.05% Tween-20 in PBS, centrifuging the tube and decanting the supernatant. The tube was then incubated  
5 with 500  $\mu$ l of goat anti-mouse antibody conjugated to glucose oxidase (from Cappel, diluted by a factor of 1000 with a 1:1 (v/v) solution of 3% BSA in PBS and .05% Tween-20 in PBS). The tube was washed 3 times by repetitively adding .05% Tween-20 in PBS, centrifuging the tube and  
10 decanting the supernatant and 2 times by adding PBS, centrifuging the tube and decanting the supernatant.

A developing solution containing 25 ml of 0.1M  $\text{Na}_3\text{PO}_4$  (pH 6.0), 3 ml of 20% glucose in  $\text{H}_2\text{O}$ , 200  $\mu$ l horseradish peroxidase (0.1% in .1M  $\text{Na}_3\text{PO}_4$ , pH 6.0) and 200  
15  $\mu$ l ABTS dye (45 mg/ml in 0.1M  $\text{Na}_3\text{PO}_4$ , pH 6.0) was prepared. A 500  $\mu$ l aliquot of the developing solution was added to the tube and allowed one hour to react with the peptide library before UV readings were taken. For the UV measurements of the assay, 900  $\mu$ l of .1M  $\text{Na}_3\text{PO}_4$  (pH 6.0)  
20 was placed in a cuvette and measured as the blank, 100  $\mu$ l of the developed solution was then introduced to the cuvette and the UV absorbance at 416 nm was monitored.

**Data Analysis.** for each ELISA, besides assaying the pentapeptide libraries, a positive and negative  
25 control were also simultaneously assayed. The positive control was the independently synthesized pentapeptide, TG-Leu-Phe-Gly-Gly-Tyr- $\text{NH}_2$ . The negative control was acetylated Tentagel (TG-Ac). The measured UV absorbance was normalized, to take into account the weight  
30 differences of the TG-resin in each assay tube, to give a normalized absorbance. The normalization was calculated by multiplying the measured absorbance at 416 nm by the mass of the material in the TG-Ac (negative control) assay tube. This product was divided by the mass of the TG-  
35 resin in the pentapeptide library tube to give the normalized absorbance. The absorbance of the negative

control was subtracted from the normalized absorbance to give a corrected absorbance.

In the early stages of the deconvolution, the negative control gave higher absorbance readings than some of the libraries. This accounts for the sub-zero absorbances seen on the graphs. As the library became more defined, fewer negative corrected absorbances were obtained.

**Quantification of Amino Acid Coupling.** A standard solution was prepared by adding DMF to a known amount of Gly-FMOC to a volume of 100 ml. 980  $\mu$ l of 20% piperidine in DMF (v/v) was scanned as a blank. 20  $\mu$ l of the Gly-FMOC solution was added to the blank, swirled for 5 minutes and scanned. The piperidine-benzofulvene complex that forms upon cleavage of the FMOC group by piperidine has a diagnostic UV absorbance peak at 302 nm. After the coupling, capping and drying steps of the combinatorial library synthesis, a determination of the completeness of each coupling was performed by taking a known mass of Tentagel resin (usually ~5 mg) from each reaction vial and placing the sample in a 1 dram vial. The vials containing the resin samples were shaken with 1000  $\mu$ l of 20% piperidine in DMF for 15 minutes. The resin was allowed to settle to the bottom and 100  $\mu$ l of the piperidine treated resin solution was added to 900  $\mu$ l of 20% piperidine in DMF which was previously added to a cuvette and scanned as a blank. The UV absorbance at 302 nm was compared to the standard to quantitate the extent of the amino acid coupling.

As a simple test of our method of deconvolution, an experiment was devised which screened libraries containing the well studied pentapeptide sequence, Leu-Phe-Gly-Gly-Tyr-NH<sub>2</sub>, which displays nanomolar binding to commercially available anti- $\beta$ -endorphin monoclonal antibody. A synthetic combinatorial peptide library with a degree of 5 and an alphabet consisting of leucin, glycine, phenylalanine and tyrosine, was synthesized on

Tentagel solid support. The total number of molecules in this library is  $4^5$  (1024 members).

The coupling of the FMOC protected amino acids to the solid support with HBTU proceeded smoothly and quantitatively, according to FMOC cleavage measurements taken after each coupling. The quantitateness of the coupling is advantageous since we can assume that the loading capacity (and therefore the number of moles per gram of resin) is approximately constant, no matter at what stage we are at in the synthesis or deconvolution of the library.

The binding assays against the  $\beta$ -endorphin antibody were performed with the peptide libraries remaining attached to the Tentagel resin. The deconvolution sequence can be followed pictorially in Figure 3 showing Scheme 3 and the corrected absorbances for each round are depicted in Figure 4. In the 4 pools of the pentapeptide libraries, where only the N-terminal amino acid was defined, TG-Xaa-Xaa-Xaa-Xaa-Tyr clearly gave the strongest absorbance. From this point, the 4 tetrapeptide libraries, TG-Xaa-Xaa-Xaa-Gly-FMOC, TG-Xaa-Xaa-Xaa-Leu-FMOC, TG-Xaa-Xaa-Xaa-Phe-FMOC and TG-Xaa-Xaa-Xaa-Tyr-FMOC, saved and labeled during the formation of the pentapeptide combinatorial library, were all coupled with Tyr-FMOC. Of the pools TG-Xaa-Xaa-Xaa-Gly-Tyr, TG-Xaa-Xaa-Xaa-Leu-Tyr, TG-Xaa-Xaa-Xaa-Phe-Tyr, and TG-Xaa-Xaa-Xaa-Tyr-Tyr, TG-Xaa-Xaa-Xaa-Gly-Tyr, obviously gave the strongest binding. This method of deconvolution was repeated to deduce that TG-Xaa-Xaa-Gly-Gly-Tyr was the best binder to the  $\beta$ -endorphin antibody. Solving for the fourth amino acid did not give a clear winner. TG-Xaa-Phe-Gly-Gly-Tyr, the sequence leading to the native epitope to the antibody, was the strongest binder. However, TG-Xaa-Leu-Gly-Gly-Tyr also showed significant binding to the antibody. Significant enough, in fact, to warrant the coupling of Leu-Gly-Gly-Tyr as well as Phe-



Gly-Gly-Tyr to the monocoupled Tentagel libraries saved from the first step of the combinatorial synthesis.

In the final analysis, TG-Leu-Phe-Gly-Gly-Tyr, the native epitope, was the most extensive binder. Other  
5 weaker binders were also deduced, TG-Phe-Phe-Gly-Gly-Tyr and TG-Leu-Leu-Gly-Gly-Tyr also showed significant binding to the  $\beta$ -endorphin antibody.

Iterative methods of deconvolution have a number of advantages. A variety of chemical libraries, not just  
10 peptide or oligonucleotide libraries, can be solved iteratively. An advantage of an iterative deconvolution over encoded libraries is that the use of a decoding tag is avoided. This averts the concern of whether the decoding tag is involved in the binding of a library  
15 member to a receptor. Also, an iterative strategy avoids the sensitivity concerns of solving for the active member of a library because iterative methods are not dependent upon sequencing or decoding for the library members bound to a receptor.

20 Making combinatorial libraries by the split pool method is a cumbersome process. By cataloguing sublibraries along each step of a combinatorial synthesis, only one library needs to be made by the split pool method. While this may not be a tremendous advantage in  
25 making libraries that are synthesized in a highly automated manner, like oligonucleotide libraries, in the synthesis of other libraries not yet amenable to automated processes, like small molecule libraries, this iterative method avoids much of the time and labor involved in  
30 making split pool libraries for the previous iterative approaches.

Other embodiments are within the following claims.

Claims

1. A kit comprising:
  - a first plurality of vessels comprising different polysubunits each constructed from a known  
5 number of subunits joined together by one or more bonds, wherein each said subunit and bond can be the same or different, each said different polysubunit comprising a different sequence of subunits but having the same known subunit at one terminus of said polysubunit, each one of  
10 said first plurality of vessels comprising polysubunits having a different known subunit at said terminus, and
  - a second plurality of vessels comprising different polysubunits each constructed from said known number minus one subunit joined together by one or more  
15 bonds, wherein each said subunit and bond can be the same or different, each said different polysubunit comprising a different sequence of subunits but having the same known subunit at one terminus of said polysubunit, each one of said second plurality of vessels comprising polysubunits  
20 having a different known subunit at said terminus.
2. The kit of claim 1, wherein said kit further comprises a third plurality of vessels comprising different polysubunits constructed from said known number minus two subunits.
- 25 3. The kit of claim 1, wherein said kit further comprises a fourth plurality of vessels comprising different polysubunits constructed from said known number minus three subunits.
- 30 4. The kit of claim 1, wherein said kit comprises further pluralities of vessels comprising different polysubunits, each said plurality of vessels differing from said other plurality of vessels in the number of subunits present in a said polysubunit.

5. The kit of claim 4, wherein said further pluralities of vessels include polysubunits differing from other pluralities of vessels by having from said known number minus two subunits to one subunit.

5           6. Method for construction of a kit useful for identification of a desired compound, comprising the steps of:

          (a) providing a first plurality of vessels comprising different polysubunits each constructed from a  
10 known number of subunits joined together by one or more bonds, wherein each said subunit and bond can be the same or different, each said different polysubunit comprising a different sequence of subunits but having the same known subunit at one terminus of said polysubunit, each said  
15 vessel comprising polysubunits having a different known subunit at said terminus,

          (b) combining aliquots of said different polysubunits from each said vessel to form a mixture, wherein said aliquots are less than all of the contents of  
20 each said vessel,

          (c) dividing said mixture into a second plurality of vessels, and

          (d) bonding a further subunit to each said polysubunit in said second plurality of vessels; wherein  
25 said subunit is different for each said second plurality of vessels.

7. The method of claim 6, wherein said method further comprises repeating said steps (a) through (d) for said second plurality of vessels.

30           8. The method of claim 7, comprising repeating said steps (a) through (d) a plurality of times.

9. Method for identification of a desired compound, comprising the steps of:

(a) providing a kit of claim 1 and screening said first plurality of vessels to identify a said vessel having a desired activity in an assay, and thereby identifying a first known subunit; and

5 (b) coupling said first known subunit to a terminus of an aliquot of the contents of each of said different polysubunits in said second plurality of vessels.


10 10. The method of claim 9, wherein said method further comprises screening said different polysubunits comprising said first known subunit for said desired activity in said assay, and thereby identifying a second known subunit.

15 11. The method of claim 9, wherein said steps (a) and (b) are repeated a plurality of times.

12. The method of claim 10, wherein said steps (a) and (b) are repeated a plurality of times.




2/5



SCHEME 2. A DECONVOLUTORY PATHWAY FOR SOLVING THE ACTIVE MEMBER OF A COMBINATORIAL LIBRARY.

FIG. 2.




SCHEME 3. ROUTE OF DECONVOLUTION OF THE TENTAGEL BOUND COMBINATORIAL PENTAPEPTIDE LIBRARY. EACH PEPTIDE POOL OF A ROUND WAS TESTED AGAINST THE ANTI- $\beta$ -ENDORPHIN ANTIBODY. THE DEFINED POSITIONS OF THE POOL WITH THE STRONGEST AND SIGNIFICANT BINDING WERE NOTED AND COUPLED TO THE APPROPRIATE SUBLIBRARY FOR THE NEXT ROUND.

FIG. 3.


4/5

FIG. 4.





5/5



CORRECTED ABSORBANCES OF EACH POOL IN COMPARISON TO THE ACETYLATED TentaGel CONTROL POOL. N DENOTES THE AMINO ACID TO BE DEFINED IN THAT ROUND. Xaa IS A RANDOMIZED POSITION.

FIG. 4 cont.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/08542

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 G01N33/68 C07K1/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 20242 (THE SCRIPPS RESEARCH INSTITUTE) 14 October 1993 see the whole document ---	1-12
A	WO,A,92 00091 (BIOLIGAND INCORPORATED) 9 January 1992 cited in the application see the whole document ---	1-12
A	WO,A,92 09300 (ITEREX PHARMACEUTICALS) 11 June 1992 cited in the application see the whole document -----	1-12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 January 1995

Date of mailing of the international search report

25. 01. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Van Bohemen, C

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 94/08542

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9320242	14-10-93	AU-B-	3944993	08-11-93
		CA-A-	2132103	14-10-93
WO-A-9200091	09-01-92	AU-A-	8238591	23-01-92
		CA-A-	2086672	03-01-92
		EP-A-	0542770	26-05-93
		JP-T-	6500308	13-01-94
		NZ-A-	238805	26-07-94
WO-A-9209300	11-06-92	CA-A-	2090860	22-05-92
		EP-A-	0558671	08-09-93
		JP-T-	6507378	25-08-94